T he apoE knockout (E0) mouse develops extensive atherosclerosis and has become one of the most widely used animal models to explore atherogenesis in vivo. [1] [2] [3] It is presumed that the remnant-like particles that accumulate in the plasma of these mice are atherogenic and induce cholesteryl ester (CE)-laden macrophages (foam cells) formation, 1 ,2 yet previous studies have shown that these plasma lipoproteins can induce only modest CE accumulation in cultured macrophages. 4 -6 The answer to this dilemma undoubtedly lies in the overall hypothesis that these lipoproteins become modified in the arterial wall to a form with increased ability to induce macrophage foam cell formation. Previous work has shown that the addition of 5 g/mL lipoprotein lipase (LpL) or the oxidation of E0 lipoproteins can increase the ability of the particles to induce foam cell formation in cultured macrophages. 4, 5 Whether there is sufficient LpL or sufficiently extensive lipoprotein oxidation in E0 lesions to facilitate these processes in vivo remains to be determined.
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A lipoprotein modification that is known to occur in lesions and that greatly enhances the ability of LDL to induce CE accumulation in macrophages is lipoprotein aggregation. [7] [8] [9] [10] [11] [12] One possible inducer of subendothelial lipoprotein aggregation is arterial wall sphingomyelinase (SMase). [13] [14] [15] [16] [17] [18] [19] SMase treatment of lipoproteins results in aggregation and fusion of the particles, and aggregated LDL isolated from human lesions, but not monomeric lesional LDL or native plasma LDL, is enriched in ceramide, a marker of SMase action on the lipoproteins. 14 A particular species of SMase called secretory SMase (S-SMase) is the best candidate for this enzyme because it is the only known extracellular SMase in mammals, it is secreted by cultured arterial wall cells, and it is found in normal endothelium and especially in atherosclerotic intima. 17 The role of S-SMase in the E0 mouse may be particularly important for the following reasons: (1) lipoproteins from the lesions of E0 mice are aggregated (Maor et al 20 and unpublished data from our researchers); (2) lipoproteins isolated from the lesions of E0 mice are enriched in ceramide 14 ; (3) E0 lesions stain abundantly for immunoreactive SMase 16 ; (4) E0 lipoproteins are among the most susceptible lipoproteins to the action of S-SMase, probably because these lipoproteins uniquely have a high sphingomyelin-to-phospholipid ratio 15, 21 ; and, most important, (5) E0 mice on a SMase knockout background have smaller lesions than E0 mice with normal SMase. 18 In light of these findings, we hypothesize that the hydrolysis of subendothelial E0 lipoproteins by arterial wall SMase converts these particles to a form that can induce macrophage foam cell formation. To test this hypothesis, we compared the ability of native and SMase-treated E0 lipoproteins to induce CE accumulation and to stimulate the cholesterol esterification pathway in macrophages. Our results show that the SMase-aggregated E0 lipoproteins are indeed potent inducers of macrophage foam cell formation. Moreover, our results indicate that a substantial portion of the cellular uptake of these aggregated particles involves the interaction of apoB with a cell-surface receptor that is uniquely competed by human hypertriglyceridemic VLDL.
Methods

Materials
The Falcon tissue culture plasticware used in these studies was purchased from Fisher Scientific Co. Tissue culture media and other tissue culture reagents were obtained from GIBCO BRL. FBS was obtained from Hyclone Laboratories. LpL was purified from bovine milk as previously described 22 and provided by Kirsten D. Mazany and Dr Kevin J. Williams. The source of S-SMase was serum-free conditioned medium harvested from DG44 Chinese hamster ovary cells stably transfected with human acid SMase cDNA. 13, 23 Bacterial SMase from Bacillus cereus, chondroitin ABC lyase from Proteus vulgaris, heparitinase from Flavobacterium heparinum, and trypsin from porcine pancreas (type IX, 13 000 U/mg) were purchased from Sigma Chemical Co. Goat anti-murine apoB was prepared and characterized as described previously 24 
Native and Modified Lipoproteins
The VLDL and LDL fraction from the plasma of chow-fed 4-to 8-month-old female or male E0 mice was prepared through preparative ultracentrifugation (dϽ1.063 g/mL). 15 S-SMase treatment of the lipoproteins was carried through the incubation of 50 L (5 g) lipoproteins in 100 mmol/L HEPES, pH 7.2, 100 mol/L ZnCl 2 with 85 L DG44 conditioned media for 16 hours at 37°C. 15 For treatment with bacterial SMase, 1 mg/mL lipoproteins was incubated with 50 mU/mL B cereus SMase for 4 hours at 37°C in PBS containing 2 mmol/L MgCl 2 . 12 LDL (dϭ1.020 to 1.063 g/mL) was isolated from fresh human plasma through preparative ultracentrifugation and acetylated as described previously. 25, 26 Oxidation was carried out by incubation of the E0 lipoproteins (1 mg/mL) with 5 mol/L CuSO 4 for 18 hours at 37°C, followed by the addition of 1 mmol/L EDTA and dialysis against 150 mmol/L NaCl, 0. 27 ; the labeled lipoproteins had a specific activity of 250 to 400 cpm/ng protein and were used within 3 weeks of iodination. S f 100-400 VLDL from a man with a plasma triglyceride level of 1320 mg/dL was obtained through preparative NaBr ultracentrifugation (dϽ1.006 g/mL), followed by discontinuous NaCl gradient centrifugation. 28 Trypsinized hypertriglyceridemic VLDL, which was generously provided by Drs Sandra Gianturco and William Bradley, was prepared through the incubation of hypertriglyceridemic VLDL with 10 mg/mL trypsin (Worthington 3ϫ crystallized) for 2 hours at 37°C, followed by reisolation through ultracentrifugation. 29 
Cells
J774.A1 macrophages (American Type Culture Collection) were maintained in spinner culture in DMEM, 10% (v/v) FBS containing 50 U/mL penicillin, 50 U/mL streptomycin, and 2 mmol/L glutamine. The medium was replaced with fresh medium each day. Mouse peritoneal macrophages from 25-to 35-g female C57BL6/J mice and from various gene-targeted mice were harvested from the peritoneum 3 days after the intraperitoneal injection of 40 g concanavalin A in 0.5 mL PBS. 30 ApoE, LDLR, and class A scavenger receptor knockout mice were obtained from Jackson Laboratories, and CD36 knockout mice were kindly provided by Drs Maria Febbraio and Roy Silverstein (Weill Medical College of Cornell University, New York, NY). The cells were plated onto 22-mm dishes in DMEM containing
, 100 U/mL penicillin, 100 g/mL streptomycin, and 292 g/mL glutamine and were used within 3 days.
Cellular Assays
Lipid extracts of the cells were assayed for total and free cholesterol mass with gas-liquid chromatography. 12 
Results
Treatment of d<1.063 Lipoproteins From E0 Mice With SMase Markedly Increases Their Ability to Induce Foam Cell Formation
To address the hypothesis that SMase-induced aggregation may contribute to foam cell formation in E0 mice, we incubated J774 macrophages with dϽ1.063 lipoproteins isolated directly from the plasma of E0 mice or with these lipoproteins after treatment with S-SMase, the enzyme proposed to induce lipoprotein aggregation in atherosclerotic lesions. 17 Note that J774 macrophages do not synthesize apoE 31 and thus provide a model for foam cell formation in apoE-deficient macrophages. In confirmation of previous results, 15, 21 S-SMase treatment led to visible lipoprotein aggregation. As shown in Figure 1A , the untreated, monomeric plasma lipoproteins caused some degree of CE accumulation in the macrophages, but the loading induced by S-SMase-aggregated lipoproteins was 5-fold higher. S-SMase alone had no effect, indicating that it was the aggregated lipoproteins and not residual SMase activity that caused the CE loading.
To determine whether the increase in CE accumulation involved stimulation of the acyl-CoA:cholesterol acyltransferase pathway, mouse peritoneal macrophages were incubated with monomeric or SMase-aggregated dϽ1.063 E0 lipoproteins in the presence of [ 14 C]oleate; for this and the following experiments, soluble bacterial SMase was used, which has the same effect on lipoproteins as human S-SMase. 12, 15 As shown in Figure 1B ( Others have proposed that E0 lipoprotein oxidation or LpL, acting as a bridging molecule, may facilitate E0 lipoprotein uptake by macrophages. 4, 5 As shown in Figure 1B , both of these perturbations indeed increased cholesterol esterification compared with untreated lipoproteins, but neither was as potent as SMase-induced aggregation. The addition of LpL to SMaseaggregated E0 lipoproteins, or SMase aggregation of oxidized E0 lipoproteins, did not increase cholesterol esterification above that seen with SMase-aggregated lipoproteins (data not shown).
The Uptake and Degradation of d<1.063 E0 Lipoproteins by Macrophages Involve an Interaction Between One or More Cell Surface Proteins and ApoB
The uptake and degradation of SMase-treated dϽ1.063 E0 lipoproteins showed evidence of saturability, as demonstrated by the concentration curve in Figure 2 . Moreover, uptake and degradation were competed 78% by unlabeled SMase-treated E0 lipoproteins (data not displayed). These data are consistent with the notion that uptake of the lipoproteins is a receptor- mediated process. To determine whether a cell-surface protein was involved, cells were treated with a limiting concentration of trypsin to effect partial hydrolysis of cell-surface proteins without otherwise damaging the cells; cycloheximide was added to prevent synthesis on new receptor protein.
As shown in Figure 3A , trypsin treatment resulted in Ϸ50% inhibition of the association of SMase-treated E0 lipoproteins with macrophages. In a parallel experiment, trypsin treatment of macrophages inhibited the cell association of acetyl-LDL, a lipoprotein known to interact with cell-surface receptor proteins, 32 by 60% (data not shown). Thus, the lack of complete inhibition of SMase-treated E0 lipoprotein uptake by trypsin most likely represents incomplete hydrolysis of cell-surface proteins under the conditions of this experiment.
The major protein on E0 lipoproteins is apoB-48. 1,2 Figure  3B shows the results of an experiment in which a polyclonal antibody that recognizes murine apoB (both B-100 and B-48) was tested for its ability to inhibit the uptake and degradation of SMase-treated E0 lipoproteins. As shown, the anti-apoB antibody inhibited uptake by 40% compared with a similar incubation with a nonimmune IgG. The lack of complete inhibition could be due to the roles of other proteins on the aggregated E0 lipoproteins, partial uptake by Fc receptors despite our attempts to block these receptors (see Methods), or less-than-complete antibody binding to the apoB on the lipoproteins. In summary, at least a substantial portion of the interaction of macrophages with SMase-treated E0 lipoproteins involves the interaction of apoB on the lipoproteins with a cell-surface receptor on the macrophages.
Preliminary Investigation Into Possible Receptors That Mediate the Uptake of SMase-Treated E0 Lipoproteins by Macrophages
Although the LDL receptor would not be expected to mediate the uptake of SMase-treated E0 lipoproteins, we tested this possibility by comparing the degradation of SMase-treated ). Finally, the treatment of macrophages with chondroitin ABC lyase plus heparitinase had no effect on lipoprotein uptake (data not shown; see Tabas et al 22 ). Thus, neither members of the LDL receptor family, members of the scavenger receptor family, nor cell-surface glycosaminoglycans appear to mediate the interaction of macrophages with SMase-treated E0 lipoproteins.
Gianturco et al 28 and Bradley et al 33 demonstrated that a cell-surface protein on macrophages recognizes apoB-48 on S f 100-400 VLDL from hypertriglyceridemic subjects (htgV-LDL). Although the physiological role of this cell-surface protein is not yet known, we considered the possibility that it or another receptor for apoB-48 -rich lipoproteins may also recognize the apoB-48 on SMase-treated E0 lipoproteins. Figure 3C shows a competitive inhibition experiment in which the abilities were compared of unlabeled LDL, oxidized LDL, and S f 100-400 htgVLDL to block the uptake and degradation of SMase-treated 125 I-E0 lipoproteins. In corroboration of the data above, neither LDL nor oxidized LDL was a competitor. htgVLDL, however, was a potent competitor, and similar results were obtained with trypsinized htgVLDL (data not shown), which is a particularly potent ligand for the macrophage protein that recognizes apoB-48. 28 htgVLDL also inhibited the uptake of SMase-aggregated E0 lipoproteins by macrophages from apoE knockout mice (60% inhibition) and from LDL receptor knockout mice (70% inhibition), indicating that the portion of the interaction that was inhibitable by htgVLDL involved neither apoE nor the LDL receptor. Importantly, htgVLDL was a relatively poor competitor of degradation of monomeric 125 I-labeled E0 lipoproteins (only 12.6% inhibition) and of 125 I-acetyl-LDL (no inhibition), indicating a lack of toxic effects of htgVLDL and specificity of competition for SMase-aggregated E0 lipoproteins. Thus, the macrophage receptor activity that mediates the uptake of SMase-treated E0 lipoproteins is uniquely competed by S f 100-400 human htgVLDL.
Discussion
The major objective of the present study was to suggest a new hypothesis as to how macrophage foam cells form in the widely studied E0 mouse model of atherosclerosis. Lipoproteins isolated directly from the plasma of these mice induce only a small amount of CE accumulation in macrophages compared with modified lipoproteins, 4 -6 and therefore these particles in their native state are unlikely to induce the massive CE accumulation seen in actual atherosclerotic lesions from these mice. In fact, the answer to this important dilemma is undoubtedly multifactorial. In addition to SMaseinduced aggregation, others have shown, and we have verified, that the addition of LpL or oxidation of E0 particles can increase cholesterol esterification in macrophages. SMase was the most potent inducer (Figure 1B) , and the addition of LpL to SMase-induced aggregates or the oxidation of E0 lipoproteins before SMase aggregation did not further enhance cholesterol esterification. Moreover, preliminary in vivo studies that show E0 mice without SMase have smaller lesions support a role for SMase in the promotion of atherogenesis in E0 mice. 18 Nevertheless, the lesions of E0 mice probably contain a variety of modified particles, and each may contribute to macrophage foam cell formation.
Regarding other possible mechanisms of foam cell formation in E0 mice, Hayek et al 34 proposed that HDL from E0 mice is a relatively poor inducer of cholesterol efflux from macrophages, so it is possible that this factor also contributes to macrophage CE accumulation in this model. The role of macrophage-secreted apoE is uncertain. The hypothesis that macrophage-secreted apoE promotes cholesterol efflux has been supported by the results of three in vivo studies: transplantation of E0 bone marrow into wild-type mice led to increased lesion development compared with transplantation of wild-type marrow into these mice, 35 and macrophagetargeted expression of apoE in E0 mice, or transplantation of apoE-expressing bone marrow into E0 mice, led to a reduction in early lesion size. 36, 37 In another study, however, the hypothesis that macrophage-secreted apoE might contribute to particle uptake was supported by the finding that the transplantation of E0 bone marrow into wild-type mice (the same strategy of the first study mentioned above) led to a reduction in early lesion size. 38 In the present study, the internalization of E0 particles and the stimulation of cholesterol esterification were similar in macrophages from E0 mice versus those from wild-type mice.
We also presented some initial findings related to how SMase-aggregated E0 lipoproteins are recognized by macrophages. The data in Figures 2 and 3A strongly suggest that a cell-surface protein mediates at least a substantial portion of this interaction. A substantial portion of lipoprotein uptake could be inhibited by an antibody that recognizes murine apoB, and because most of the apoB on E0 lipoproteins is apoB-48, these data suggest an important role for this protein.
The ability of native and trypsinized S f 100-400 htgVLDL to inhibit the uptake of SMase-aggregated E0 lipoproteins is consistent with this idea, because a macrophage cell-surface protein that recognizes these VLDLs has been shown to bind apoB-48. 28, 33 The actual physiological function of this particular cell-surface protein, however, has not yet been elucidated, and its possible role in foam cell formation in E0 mice must await gene knockout studies.
There are several fundamental aspects of atherogenesis that are addressed by the findings in this report. First, the E0 mouse has been one of the most widely used models of atherosclerosis, and the presence of large numbers of macrophages with massive CE accumulation in the lesions of these mice is one of the most important characteristics of the model. Thus, the knowledge of how foam cells form in this model is critical for studies that address mechanisms of atherogenesis in E0 mice as well as for those that explore genetic, pharmacological, and dietary interventions to prevent lesions or to reduce lesion size. Second, the principle that modification of plasma lipoproteins in the subendothelium of developing lesions is necessary for foam cell formation is directly applicable to LDL-induced atherosclerosis in animals and humans. 9, 39, 40 In particular, native plasma LDL is a weak inducer of CE loading in macrophages, but aggregated LDL, which is prominently found in atherosclerotic lesions, is a potent inducer of cholesterol esterification in macrophages. 10 -12 Because aggregated LDL from human lesions shows evidence of SMase hydrolysis, 14 the findings in the present report suggest that the E0 model may be a reasonable model with which to explore the role of SMase in human atherogenesis. Third, although apoE deficiency is an extremely rare cause of human atherosclerosis, functional mutations in this protein can lead to a more common disease, namely, familial dysbetalipoproteinemia (type III hyperlipoproteinemia). 41, 42 Type III VLDL from most patients is only a modest inducer of CE accumulation in macrophages, 43, 44 so the mechanisms of foam cell formation in the lesions of these subjects may share characteristics with foam cell formation in E0 mice. Finally, the particles that accumulate in E0 mice share some properties with those of chylomicron remnants in humans, 1,2 which are thought to be atherogenic and which may be quite abundant in the postprandial state. 45 Interestingly, human chylomicron remnants, unlike those that accumulated in fat-fed rabbits or dogs, 46 are rather weak inducers of cholesterol esterification in cultured macrophages. 47, 48 Thus, modification in the arterial wall by SMase may represent one mechanism that links these particles to atherosclerosis and heart disease in humans.
